Yulia Valko

Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis

Myasthenia gravis: the changing treatment landscape in the era of molecular therapies

Repetitive ocular vestibular evoked myogenic potential stimulation for the diagnosis of myasthenia gravis: Optimization of stimulation parameters

Ocular vestibular evoked myogenic potentials as a test for myasthenia gravis